ABVC ABVC BioPharma, Inc.
Distress ·
ABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period.
ABVC reported stockholders' equity of $723,959, below the $2,500,000 Nasdaq minimum. It also sold shares to 15 non-U.S. buyers for a little more than $436,000.
The company says it is still completing its audit for the year ended December 31, 2024 and expects to file the 10-K within 15 calendar days of the due date. It does not expect a significant change in results.
ABVC said it is still completing its audit and other disclosures. It expects to file the Form 10-K within the 15-day extension period.
It is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing.
| Line | FY2025 | FY2024 |
|---|---|---|
| Revenue | $509,589 | |
| Research and development | $121,085 | $179,272 |
| Net income (loss) | -$7.9 million | -$4.9 million |
| Cash from operations | -$3.0 million | -$1.8 million |
| Cash and equivalents | $681,480 | $248,382 |
| Short-term investments | $64,354 | $64,736 |
Our latest story on this, dated May 15, 2026: "ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026". The story links the filing or release it is based on. Read the story.
ABVC BioPharma, Inc. trades under the ticker ABVC on NASDAQ.
ABVC BioPharma, Inc. is listed on NASDAQ.
The SEC Central Index Key (CIK) for ABVC BioPharma, Inc. is 1173313. Its filings are on SEC EDGAR.
26,654,365 shares as of 2026-08-10, per the cover page of its 10-Q filed 2026-08-12.
Our directory records ABVC BioPharma, Inc. under United States.
Our directory classifies ABVC BioPharma, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for ABVC BioPharma, Inc. is US00091F3047.
aibio.space lists ABVC BioPharma, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as NV.
ABVC BioPharma, Inc. reported a net loss of $7.9 million for the fiscal year ended Dec 31, 2025, and used $3.0 million of cash in operations, per its annual report to the SEC.
$121,085 in the fiscal year ended Dec 31, 2025, per its annual report.
$94,364 in cash and short-term investments at Jun 30, 2026, per its 10-Q.
Our latest story on ABVC BioPharma, dated May 15, 2026: "ABVC BioPharma files NT 10-Q late-filing notice for quarter ended March 31, 2026". ABVC says it could not finalize its Form 10-Q and XBRL exhibit before the deadline without unreasonable effort or expense. Management believes it can file within the extension period. Source.
Our latest financing story, dated Jan 6, 2025: "ABVC BioPharma cuts warrant price to $0.40 as Lind agrees to exercise 1,029,167". It is the third such letter agreement with Lind Global Fund II, LP. The company agreed not to issue new shares for 15 days after closing. Source.
Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.01,2.01,7.01,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 2.02,4.02,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,3.02,9.01). Source
Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source
Said earlier financial statements should no longer be relied on. SEC Form 8-K (Items 2.02,4.02,7.01,9.01). Source
Told the SEC a periodic report would be filed late. SEC Form NT 10-K. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio